Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1635 1636 1674 1682 4100
This examiner grants 75% of resolved cases
Amy Rose Hudson is an experienced examiner in Tech Center 4100, Art Unit 1635, with 1457 resolved cases. She maintains an allowance rate of 74.9%, which is quite high for such a large volume of cases. The median days to allowance is 893, showing a high level of efficiency in her prosecution process. The 1457 resolved cases provide a very stable statistical profile for practitioners to rely on when filing in this art unit.
The interview lift of 11.5% shows that even with a 74.9% allowance rate, interviews provide a clear benefit to the probability of grant. Practitioners can rely on the 893-day median pendency when advising clients on timelines in Tech Center 4100. Her consistent performance across 1457 cases makes her a predictable examiner. The 11.5% lift suggests that direct communication remains a useful tool for resolving any outstanding issues. The 74.9% allowance rate indicates a generally receptive environment for patentability. These metrics suggest that Art Unit 1635 offers a relatively smooth path to allowance under her supervision.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18288225 | GENE THERAPIES FOR STARGARDT DISEASE (ABCA4) | Non-Final OA | University of Massachusetts |
| 18287909 | MATERIALS AND METHODS FOR IMPROVING EFFICACY OF ADOPTIVE IMMUNE CELL THERAPY | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 18671569 | GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION | Non-Final OA | BAYER HEALTHCARE LLC |
| 17052798 | IN VIVO HOMOLOGY DIRECTED REPAIR IN HEART, SKELETAL MUSCLE, AND MUSCLE STEM CELLS | Non-Final OA | President and Fellows of Harvard College |
| 18340582 | GENETIC ELEMENTS DRIVING CIRCULAR RNA TRANSLATION AND METHODS OF USE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18516523 | PLASMA CELL-FREE RNA AND METHODS OF USE THEREOF AS NON-INVASIVE BIOMARKERS FOR ALZHEIMER'S DISEASE | Non-Final OA | WASHINGTON UNIVERSITY |
| 18560348 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18510900 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | Final Rejection | The Governors of the University of Alberta |
| 18605332 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | Non-Final OA | The General Hospital Corporation |
| 18246594 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18248982 | NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 | Final Rejection | SANOFI |
| 17638339 | COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 | Non-Final OA | SANOFI |
| 18273357 | RNAI NANOPARTICLES AND METHODS OF USING SAME IN AGRICULTURE | Non-Final OA | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | Final Rejection | University of Virginia Patent Foundation |
| 18306680 | THERAPEUTIC TARGETING OF ACTIVATED AVIL-INDUCED SARCOMAS | Final Rejection | University of Virginia Patent Foundation |
| 18622162 | METHOD FOR MODULATING UNPRODUCTIVE ALTERNATIVE SPLICING | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18290373 | COMPOSITION, FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE, COMPRISING miRNA INHIBITOR, AND USE THEREOF | Final Rejection | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18326912 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 18016109 | METHODS AND COMPOSITIONS FOR CRISPR/CAS9 GUIDE RNA EFFICIENCY AND SPECIFICITY AGAINST GENETICALLY DIVERSE HIV-1 ISOLATES | Non-Final OA | Trustees Of Dartmouth College |
| 17906444 | HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID | Final Rejection | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 17602035 | Pharmaceutical Composition for Treating Muscle Disease | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 18434928 | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18548634 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC |
| 18136386 | MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 18030745 | NOVEL TARGETS FOR REACTIVATION OF PRADER-WILLI SYNDROME-ASSOCIATED GENES | Non-Final OA | Duke University |
| 18249248 | INDUCTION OF FERROPTOSIS FOR CANCER THERAPY | Non-Final OA | Memorial Sloan Kettering Cancer Center |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy